{
    "clinical_study": {
        "@rank": "107548", 
        "arm_group": [
            {
                "arm_group_label": "LEO 90100", 
                "arm_group_type": "Experimental", 
                "description": "-"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to compare the efficacy of treatment with LEO 90100 to that of\n      treatment with vehicle for up to 4 weeks in subjects with psoriasis vulgaris."
        }, 
        "brief_title": "LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Psoriasis Vulgaris", 
            "Plaque Psoriasis"
        ], 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A clinical diagnosis of psoriasis vulgaris of at least 6 months duration involving\n             the trunk and/or limbs\n\n          -  Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and\n             skin folds) involving 2-30% of the Body Surface Area (BSA)\n\n          -  An Investigator's Global Assessment of disease severity (IGA) of at least mild at Day\n             0 (Visit 1)\n\n          -  A modified PASI (m-PASI) score of at least 2 at Day 0 (Visit 1)\n\n          -  A target lesion of a minimum of 5 cm at its longest axis and preferably not located\n             on the extensor surface on an elbow or knee, scoring at least 1 for each of redness,\n             thickness and scaliness, and at least 4 in total by the Investigator's Assessment of\n             Severity of the Target Lesion\n\n        Exclusion Criteria:\n\n          -  Systemic treatment with biological therapies, whether marketed or not, with a\n             possible effect on psoriasis vulgaris within the following time periods prior to\n             randomisation:\n\n               -  etanercept - within 4 weeks prior to randomisation\n\n               -  adalimumab, infliximab - within 8 weeks prior to randomisation\n\n               -  ustekinumab - within 16 weeks prior to randomisation\n\n               -  other products - within 4 weeks/5 half-lives prior to randomisation (whichever\n                  is longer)\n\n          -  Systemic treatment with all other therapies with a possible effect on psoriasis\n             vulgaris (e.g., corticosteroids, retinoids, methotrexate, ciclosporin and other\n             immunosuppressants) within 4 weeks prior to randomisation.\n\n          -  Subjects who have received treatment with any nonmarketed drug substance (i.e. a drug\n             which has not yet been made available for clinical use following registration) within\n             4 weeks/5 half-lives (whichever is longer) prior to randomisation.\n\n          -  PUVA therapy within 4 weeks prior to randomisation.\n\n          -  UVB therapy within 2 weeks prior to randomisation.\n\n          -  Topical anti-psoriatic treatment on the trunk and limbs (except for emollients)\n             within 2 weeks prior to randomisation.\n\n          -  Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D\n             analogues or prescription shampoos within 2 weeks prior to randomisation.\n\n          -  Planned initiation of, or changes to, concomitant medication that could affect\n             psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors)\n             during the trial.\n\n          -  Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.\n\n          -  Previously randomised in this trial or any previously conducted trial of LEO 90100."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "426", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01866163", 
            "org_study_id": "LP0053-1001"
        }, 
        "intervention": [
            {
                "arm_group_label": "LEO 90100", 
                "intervention_name": "LEO 90100", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63117"
                }, 
                "name": "Central Dermatology"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris", 
        "overall_official": {
            "affiliation": "Central Dermatology", 
            "last_name": "Craig Leonardi", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Subjects with 'treatment success' ('clear' or 'almost clear' for subjects with at least moderate disease at baseline, 'clear' for subjects with mild disease at baseline) according to the Investigators' global assessment of disease severity (IGA) at Week 4.", 
            "measure": "Treatment Success according to IGA", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01866163"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "m-PASI at Week 4.", 
                "measure": "Psoriasis Area Severity Index (a measure combining redness, thickness, scaliness and extent) assessed at week 4", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "m-PASI at Week 1.", 
                "measure": "Psoriasis Area Severity Index (a measure combining redness, thickness, scaliness and extent) assessed at week 1", 
                "safety_issue": "No", 
                "time_frame": "1 week"
            }
        ], 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}